Using a low-dose contraceptive in women 35 years of age and over: 20 μg estradiol/100 μg levonorgestrel

Contraception

Volumn 65, Issue 6, 2002, Pages 397-402

  Carr, Bruce R ^a   DelConte, Anthony ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Wyeth Ayerst Research   (United States)

Author keywords

Ethinyl estradiol; Levonorgestrel; Low dose oral contraceptive; Perimenopause

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; CONTRACEPTIVE AGENT; ESTRADIOL DERIVATIVE; ETHINYLESTRADIOL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MENSTRUAL CYCLE; METRORRHAGIA; NORMAL HUMAN; PREGNANCY; DOSE RESPONSE; DRUG COMBINATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, SYNTHETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ESTROGENS, SYNTHETIC; ETHINYL ESTRADIOL; FEMALE; HUMAN; LEVONORGESTREL; MENSTRUAL CYCLE; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; ESTRADIOL CONGENERS; HUMANS;

EID: 0036597741     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(02)00292-5     Document Type: Article

References (54)

1. The perimenopausal transition
2. Unintended pregnancy in the United States
3. Maternal mortality in women aged 35 years or older: United States
4. Fertility in older women
5. Contraception for women over 35 years of age
6. Contraception for the transitional years of women older than 40 years of age
7. Rational use of oral contraceptives in the perimenopausal woman
8. The effect of 20 μg ethinyl estradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women
9. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: A three-year prospective study
10. Oral contraceptive use during the perimenopausal years
11. Oral contraceptives and bone mineral density: A population-based study
12. Oral contraceptive use may protect against low bone mass
13. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use
14. The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women
15. Hormone replacement therapy in perimenopause: Effect of a low dose oral contraceptive preparation on bone quantitative ultrasound characteristics
16. Longitudinal evaluation of perimenopausal vertebral bone loss: Effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism
17. Longitudinal evaluation of perimenopausal femoral bone loss: Effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism
18. The reduction in risk of ovarian cancer associated with oral contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development
19. Oral contraceptives and ovarian cancer
20. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer
21. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development
22. Noncontraceptive benefits of oral contraceptives
23. Oral contraceptives and endometrial cancer
24. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 μg and ethinyl estradiol 20 μg
25. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse)
26. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 μg/20 μg versus triphasic norethindrone/ethinylestradiol 500-750-1000 μg/35 μg: A multicenter, randomized, open-label study
27. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol
28. The changes before 'the change.' Strategies for the transition to the menopause
29. Oral contraceptives: Therapeutic uses and quality-of-life benefits - Case presentations
30. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives
31. Oral contraceptives and epithelial ovarian cancer: Does dose matter?
32. Oral contraceptives and the risk of hereditary ovarian cancer
33. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation
34. Oral contraceptives and colorectal tumors. A review of epidemiologic studies
35. Oral contraceptives and colorectal cancer risk: A meta-analysis
36. Effects of an oral contraceptive combination containing 0.150 mg desogestrel plus 0.020 mg ethinyl estradiol on healthy premenopausal women
37. Biochemical aspects of hormonal contraception: Effects on bone metabolism
38. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). A randomized controlled trial
39. Oral contraceptive use and risk of hip fracture: A case-control study
40. Weight change and adverse event incidence with a low-dose oral contraceptive: Two randomized, placebo-controlled trials
41. Determinants of long-term hormone replacement therapy and reasons for early discontinuation
42. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg oestrogen preparations
43. Oral contraception and risk of a cerebral thromboembolic attack: Results of a case-control study
44. Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study
45. Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study
46. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: Results of an international, multicentre, case-control study
47. Stroke in users of low-dose oral contraceptives
48. Low-dose oral contraceptive use and the risk of myocardial infarction
49. Risk factors for acute myocardial infarction in women: Evidence from the Royal College of General Practitioners' Oral Contraception Study
50. Further analyses of mortality in oral. Royal College of General Practitioners' Oral Contraception Study
51. Past use of oral contraceptives and cardiovascular disease: A meta-analysis in the context of the Nurses' Health Study
52. Oral contraceptive use in perimenopause